The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Open accessAbstract
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. Representatives from the American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and the World Health Organization also participated in the development of the guideline. This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. For all recommendations, literature reviews were performed, followed by discussion by an expert committee according to the Grading of Recommendations, Assessment, Development and Evaluation methodology. Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence of comorbidities, severity of disease, and response to treatment influence management decisions. Specific recommendations on the use of case management strategies (including directly observed therapy), regimen and dosing selection in adults and children (daily vs intermittent), treatment of tuberculosis in the presence of HIV infection (duration of tuberculosis treatment and timing of initiation of antiretroviral therapy), as well as treatment of extrapulmonary disease (central nervous system, pericardial among other sites) are provided. The development of more potent and better-tolerated drug regimens, optimization of drug exposure for the component drugs, optimal management of tuberculosis in special populations, identification of accurate biomarkers of treatment effect, and the assessment of new strategies for implementing regimens in the field remain key priority areas for research. See the full-text online version of the document for detailed discussion of the management of tuberculosis and recommendations for practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
The Impact of Medical Interpreter Services on the Quality of Health Care: A Systematic Review
Flores, G. (2005) · Medical Care Research and Review · doi:10.1177/1077558705275416 · Cited by 1,667
Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research
Munro, S. A., Lewin, S. A., Smith, H. J., Engel, M. E., Fretheim, A., & Volmink, J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040238 · Cited by 1,080
Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults
Thwaites, G. E., Bang, N. D., Dung, N. H., Quy, H. T., Oanh, D. T. T., Thoa, N. T. C., Hien, N. Q., Thuc, N. T., Hai, N. N., Lan, N. T. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040573 · Cited by 1,043
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1666st · Cited by 912
Self-citationThe impact of diabetes on tuberculosis treatment outcomes: A systematic review
Baker, M. A., Harries, A. D., Jeon, C. Y., Hart, J. E., Kapur, A., Lönnroth, K., Ottmani, S.-E., Goonesekera, S. D., & Murray, M. B. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-81 · Cited by 881
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
Meintjes, G., Lawn, S. D., Scano, F., Maartens, G., French, M. A., Worodria, W., Elliott, J. H., Murdoch, D., Wilkinson, R. J., Seyler, C., et al. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70184-1 · Cited by 745
Fox, W., Ellard, G. A., & MITCHISON, D. A. (1999) · PubMed · Cited by 676
Thwaites, G., Fisher, M., Hemingway, C., Scott, G., Solomon, T., & Innes, J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.06.011 · Cited by 666
Cited by
Point-of-care diagnostics for infectious diseases: From methods to devices
Wang, C., Liu, M., Wang, Z., Li, S., Deng, Y., & He, N. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101092 · Cited by 622
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Self-citationSalcedo, J., Rosales, M., Kim, J. S., Nuno, D., Suen, S.-C., & Chang, A. H. (2021) · PLOS ONE · doi:10.1371/journal.pone.0254950 · Cited by 41
Tuberculous Lymphadenitis and Parotitis.
Cataño, J. C., & Robledo, J. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tnmi7-0008-2016 · Cited by 35
Metadata
- Authors
- Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., Peloquin, C. A., Raftery, A., Saukkonen, J., Schaaf, H. S., Sotgiu, G., Starke, J. R., Migliori, G. B., & Vernon, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-01
- Volume
- 63
- Issue
- 7
- Pages
- 853-867
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4235935369
- Cited by
- 326
- References
- 69
- FWCI
- 28.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. https://app.cochat.ai/papers/10.1093/cid/ciw566
- The paper
- Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., . . . Vernon, A. (2016). Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciw566
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.